AACR 2020: Oral PD-L1 inhibitor CCX559, anti-tumor effect in mice better than PD-1/PD-L1 monoab

Data presented by ChemoCentryx at the 2020 American Cancer Research Association (AACR) virtual meeting showed that the company's optimized oral checkpoint inhibitor CCX559 significantly inhibits PD-1/PD-L1 interactions, in vitro signaling, and has an effective anti-tumor effect in animal modelsThe company plans to launch clinical development of CCX559 in the first half of 2021Photo Source: DrThomas JSchall, President and CEO ofChemoCentryx, said, "We are developing new, efficient, highly specific oral checkpoint inhibitors with the goal of providing patients with more convenient approaches and good safetyOur oral small molecule inhibitors are easy to use and flexible to administer, allowing more detailed regulation of checkpoint suppression to fight tumors and avoid side effects"
The PD-1/PD-L1 pathway helps tumor cells escapesurveillanceimmune systemInhibition of PD-L1 has the potential to prevent PD-1 from binding to PD-L1, thereby exposing tumor cells to the anti-tumor effects of the immune systemChemoCentryx optimizes several small molecule PD-L1 inhibitors designed to disrupt the interaction of PD-1 with PD-L1Active compounds were found to be very effective in the assessment of tumor cell killing mediated by mixed lymphocyte reaction (MLR) and peripheral blood mononucleosis (PBMC)the evaluation of tumor microenvironment in mouse tumor models showed that the lead compound almost completely blocked the interaction of PD-L1 on tumor cells with PD-1 on immune-effect cells, thus enhancing the immune response of antitumors Importantly, in the invivia model, ChemoCentsmall small molecular inhibitors have consistently performed better than antibodies that are resistant to PD-1/PD-L1